Proof-of-concept study shows microbiome sequencing distinguishes urothelial carcinoma from benign bladder tissue, indicating therapy effects.
This proof-of-concept study suggests that: (1) microbiome sequencing from FFPE TURBT specimens can be used for microbiota assessment and can effectively distinguish UCC from benign pathology. (2) bladder microbiomes are heavily depleted following BCG treatment, indicating therapy-induced microbiome alterations.
No takes yet. Share an insight, caveat, or question.
Pearson et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: